{"doi":"10.1371/journal.pmed.1004582","title":"Dihydroartemisinin–piperaquine plus sulfadoxine–pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda","abstract":"BACKGROUND: To mitigate adverse consequences of malaria in pregnancy, the World Health Organization recommends intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine. However, the effectiveness of IPTp with sulfadoxine-pyrimethamine has been threatened by widespread Plasmodium falciparum resistance, especially in East and Southern Africa. For IPTp, dihydroartemisinin-piperaquine has shown superior antimalarial effects compared to sulfadoxine-pyrimethamine, but sulfadoxine-pyrimethamine has been associated with improved birth outcomes compared to dihydroartemisinin-piperaquine. We hypothesized that a combination of both dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine would provide superior birth outcomes compared to either drug alone. METHODS AND FINDINGS: We conducted a double-blinded, randomized, controlled trial of 2,757 pregnant women in Uganda, where resistance of malaria parasites to sulfadoxine-pyrimethamine is widespread. Women were randomly assigned (1:1:1) to monthly IPTp with sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine, or dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine. The primary outcome was the risk of a composite adverse birth outcome defined as any of the following: spontaneous abortion, stillbirth, low birthweight (LBW, < 2,500 g), preterm delivery (<37 weeks), small-for-gestational age, or neonatal death. Secondary outcomes included specific individual adverse birth outcomes, measures of malaria during pregnancy, and safety/tolerability. Combining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine did not reduce the risk of a composite adverse birth outcome compared to dihydroartemisinin-piperaquine (30.0% versus 30.9%, relative risk (RR) 0.97 [95% CI 0.84-1.12]; p = 0.70) or sulfadoxine-pyrimethamine (30.0% versus 26.4%, RR 1.14 [95% CI 0.98-1.33]; p = 0.10). The risk of a composite adverse birth outcome was higher with dihydroartemisinin-piperaquine compared to sulfadoxine-pyrimethamine (30.9% versus 26.4%, RR 1.17 [95% CI 1.01-1.36]; p = 0.04). Considering individual adverse birth outcomes, combining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine was associated with a higher risk of small-for-gestational age (23.4% versus 18.7%, RR 1.25 [95% CI 1.04-1.51]; p = 0.02) and low birthweight (8.6% versus 5.8%, RR 1.48 [95 CI 1.04-2.12]; p = 0.03) compared to sulfadoxine-pyrimethamine and a higher risk of preterm delivery (5.3% versus 3.1%, RR 1.73 [95% CI 1.07-2.79]; p = 0.03) compared to dihydroartemisinin-piperaquine. During pregnancy, compared to sulfadoxine-pyrimethamine, dihydroartemisinin-piperaquine was associated with a 94% reduction in the incidence of symptomatic malaria (0.46 versus 0.03 episodes per person-year, incidence rate ratio 0.06 [95% CI 0.03-0.12]; p < 0.001) and a 97% reduction in the risk of microscopic parasitemia (17.7% versus 0.6%, RR 0.03 [95% CI 0.02-0.05]; p < 0.001), but dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine was not associated with improved malaria outcomes over dihydroartemisinin-piperaquine alone. There were no significant differences in the incidence of any grade 3-4 adverse events between the treatment arms. As this study was conducted in an area of high transmission intensity with widespread resistance to sulfadoxine-pyrimethamine, findings may not be generalizable to other settings. CONCLUSIONS: Despite the superior antimalarial activity of dihydroartemisinin-piperaquine, sulfadoxine-pyrimethamine alone was associated with improved birth outcomes. Combining dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine for IPTp did not improve birth outcomes compared to either sulfadoxine-pyrimethamine or dihydroartemisinin-piperaquine alone. TRIAL REGISTRATION: ClinicalTrials.gov (NCT04336189; https://clinicaltrials.gov/study/NCT04336189).","journal":"PLoS Medicine","year":2025,"id":513094,"datarank":0.45815421370616993,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.08541821623796982,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.08541821623796982,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":6,"citers_with_citation_signal":3,"citers_with_endowment":3,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9492,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04336189"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1087437,"name":"Jimmy Kizza","orcid":"0000-0003-0224-4044","position":1,"is_corresponding":false},{"id":1278815,"name":"Miriam Aguti","orcid":"0009-0005-8885-6931","position":2,"is_corresponding":false},{"id":1004134,"name":"Harriet Adrama","orcid":null,"position":3,"is_corresponding":false},{"id":455323,"name":"John Ategeka","orcid":"0000-0002-6604-2532","position":4,"is_corresponding":false},{"id":621664,"name":"Peter Olwoch","orcid":"0000-0002-7396-3348","position":5,"is_corresponding":false},{"id":455380,"name":"Miriam Nakalembe","orcid":"0000-0001-7569-8173","position":6,"is_corresponding":false},{"id":260122,"name":"Joaniter I. Nankabirwa","orcid":"0000-0001-7818-3845","position":7,"is_corresponding":false},{"id":455961,"name":"Bishop Opira","orcid":null,"position":8,"is_corresponding":false},{"id":305910,"name":"Nida Özarslan","orcid":"0000-0003-3235-1238","position":9,"is_corresponding":false},{"id":1373395,"name":"Anju Ranjit","orcid":"0000-0002-7203-6710","position":10,"is_corresponding":false},{"id":1373396,"name":"Erin J. dela Cruz","orcid":"0000-0002-3380-5353","position":11,"is_corresponding":false},{"id":255292,"name":"Tamara D. Clark","orcid":"0000-0003-1109-6039","position":12,"is_corresponding":false},{"id":729900,"name":"Michelle E. Roh","orcid":"0000-0002-6268-0801","position":13,"is_corresponding":false},{"id":273919,"name":"Stephanie L. Gaw","orcid":"0000-0003-0891-6964","position":14,"is_corresponding":false},{"id":233149,"name":"Prasanna Jagannathan","orcid":"0000-0001-6305-758X","position":15,"is_corresponding":false},{"id":242457,"name":"Philip J. Rosenthal","orcid":"0000-0002-7953-7622","position":16,"is_corresponding":false},{"id":242453,"name":"Moses R. Kamya","orcid":"0000-0001-9106-4234","position":17,"is_corresponding":false},{"id":242454,"name":"Grant Dorsey","orcid":"0000-0003-0740-0317","position":18,"is_corresponding":false},{"id":367278,"name":"Abel Kakuru","orcid":"0000-0001-9941-1309","position":0,"is_corresponding":true}],"reference_count":32,"raw_metadata":null,"created_at":"2026-07-19T02:48:11.233009Z","pmid":"40966190","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}